Results 371 to 380 of about 98,962 (385)

Biopharmaceutical benchmarks 2010

Nature Biotechnology, 2010
Over the past four years, several new types of experimental biologic treatment have received commercial registration, but the emergence of biosimilars represents the biggest shift in the biologic approval landscape.
openaire   +3 more sources

Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.

Journal of Pharmacy and Science, 2016
S. Baghel, Helen Cathcart, Niall J. O'Reilly   +2 more
semanticscholar   +1 more source

Analysis of biopharmaceuticals

TrAC Trends in Analytical Chemistry, 2013
Gerhardus J. de Jong, Rainer Bischoff
openaire   +2 more sources

Biopharmaceutics

2002
Leon Shargel, Andrew Yu
openaire   +1 more source

Immunotoxicology of Biopharmaceutics

2010
H.G. Haggerty, K.D. Price, J.M. Shenton
openaire   +1 more source

Hyaluronic acid‐based biopharmaceutical delivery and tumor‐targeted drug delivery system

Journal of Controlled Release, 2018
G. Huang, Hualiang Huang
semanticscholar   +1 more source

Biopharmaceutical benchmarks

Nature Biotechnology, 2000
openaire   +2 more sources

The Current Scientific and Regulatory Landscape in Advancing Integrated Continuous Biopharmaceutical Manufacturing.

Trends in Biotechnology, 2019
Adam C. Fisher, M. Kamga, C. Agarabi, K. Brorson, Sau Lee, Seongkyu Yoon   +5 more
semanticscholar   +1 more source

Biopharmaceutics

2010
openaire   +1 more source

Biopharmaceutical benchmarks—2003 [PDF]

Nature Biotechnology, 2003
openaire   +2 more sources